The COL5A1 antibody targets the alpha-1 chain of type V collagen, a critical component of the extracellular matrix (ECM). Type V collagen, a fibrillar collagen, co-assembles with type I collagen to regulate the diameter and organization of collagen fibrils, ensuring structural integrity in connective tissues such as skin, tendons, and blood vessels. COL5A1 mutations are linked to Ehlers-Danlos syndrome (EDS), a group of disorders characterized by joint hypermobility, skin fragility, and tissue fragility. The antibody is widely used in research to investigate COL5A1 expression, distribution, and functional roles in ECM remodeling, wound healing, and tissue development.
In disease contexts, COL5A1 antibodies help elucidate mechanisms underlying connective tissue pathologies, including classical EDS, osteoarthritis, and fibrosis. Studies also explore its involvement in cancer progression, as altered type V collagen expression may influence tumor microenvironment interactions and metastasis. Available as monoclonal or polyclonal variants, these antibodies are validated for techniques like Western blotting, immunohistochemistry, and immunofluorescence. Specificity is confirmed using knockout controls or siRNA-treated samples.
Research using COL5A1 antibodies has expanded understanding of collagen fibrillogenesis and its dysregulation in genetic and acquired disorders, offering potential insights for therapeutic targeting of ECM-related diseases.